An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma

The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circumvent multidrug resistance. Previously, we showed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Fan, Dongmei, Jiang, Linlin, Song, Yuewen, Bao, Shiqi, Yang, Yuanyuan, Yuan, Xiangfei, Zhen, Yongsu, Yang, Ming, Xiong, Dongsheng
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737009/
https://ncbi.nlm.nih.gov/pubmed/31555598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados